Abstract:The intramuscular delivery of vectored antibody by recombinant adeno-associated virus (rAAV) holds promise for preventing and treating emerging infectious diseases. Recent studies in nonhuman primates suggested that a single intramuscular injection of rAAV1 expressing anti-SIV neutralizing antibody provided long-term protection from SIV infection. However, some of NHP recipients generated anti-antibody responses that eliminate neutralizing activity of vectored antibodies. We exploit different strategies to engineer AAV vectors that can surmount such anti-antibody responses, one of which is to induce systemic tolerance to vectored antibody. It is well established that the hepatic gene transfer can induce systemic immune tolerance to transgene products. Here, we attempted to use hepatotropic AAV serotypes and hepatocyte-specific promoter for liver-specific gene expression to induce systemic immune tolerance to muscle-expressed transgene products including intracellular β-Galactosidase (β-gal) or secreted Ovalbumin (OVA). First, we tested if the transgene specific CD8+ T cells could be reduced by using liver-specific promoter. C57BL/6 mice were intravenously delivered with rAAV9 vectors expressing β-gal from either ubiquitous chicken β-actin (CB) promoter or liver-specific human thyroxine binding globulin (TBG) promoter. When compared to CB promoter, TBG can achieve significantly higher β-gal expression with reduced β-gal specific CD8+ T cells. To compare the humoral immune responses against the secrete transgene products, AAV8 vectors expressing OVA from CB or TBG were intravenously injected to C57BL/6 mice. AAV8.TBG.OVA injected mice showed significant higher OVA expression than AAV8.CB.OVA injected mice did. Interestingly, while the mice received rAAV1CB.OVA intramuscularly triggered robust anti-OVA IgG1 response with low and transient OVA expression, such responses in the mice treated with intravenously delivered both AAV8 vectors were negligible accompanied with high levels of sustained OVA expression. In addition, the high frequency of regulatory T cells and CD19+CD5+CD1d+ regulatory B cells are detected in the spleens from the mice intravenously delivered both AAV8OVA vectors. Finally, we tested whether hepatic restricted OVA gene transfer by AAV8.TBG.OVA can indeed induce immune tolerance to subsequently and intramuscularly delivered AAV1.CB.OVA in C57BL/6 mice. Again, very low levels of transient OVA expression and high levels of anti-OVA IgG1 were detected in the animals treated with PBS followed by intramuscular AAV1.CB.OVA, whereas the intravenously delivered AAV8.TBG.OVA vectors facilitated the subsequently muscle-directed AAV1-encoded OVA expression without antibody production. Our data suggest that both regulatory T and B cells may play roles in systemic immune tolerance induced by liver-derived transgene expression from liver tropic AAV vector.

Tolerance Induction by Gene Transfer to Lymphocytes

Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffold.

Potential role for oral tolerance in gene therapy

Blockade of Inhibitor Formation by B-Cell Delivered Tolerance to Immunodominant A2 and C2 Domains.

Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors

Induction of Tolerance to Factor Viii Inhibitors by Gene Therapy with Immunodominant A2 and C2 Domains Presented by B Cells As Ig Fusion Proteins

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Gene Therapy for Tolerance to Factor VIII Induced with B Cells and Bone Marrow Transduced with FVIII Domains.

Mechanisms of Gene Therapy for Tolerance: B7 Signaling is Required for Peptide-Igg Gene-Transferred Tolerance Induction.

Progress Toward Antibody-Induced Transplantation Tolerance

Rerovirus Mediated Hsv-Tk Gene Transfer Can Influence The Function Of Human T-Lymphocyte

Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision

Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?

457. Both Regulatory T and B Cells May Play Roles in Systemic Immune Tolerance Induced by Raav-Mediated Gene Transfer to Liver

Targeting Lymphoid Tissues to Promote Immune Tolerance

Regulating Regulatory T Cells to Achieve Transplant Tolerance.

Guiding Postablative Lymphocyte Reconstitution as a Route Toward Transplantation Tolerance

Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases

Genetic engineering of T cells for immunotherapy

Lymph Node-Targeted Synthetically Glycosylated Antigen Leads to Antigen-Specific Immunological Tolerance

B cells with regulatory properties in transplantation tolerance